Company Profile

GH Research Stock Price, News & Catalysts

Ticker:
GHRS
Exchange:
NASDAQ
Sector:
Biopharma
Location:
Ireland and listed in the U

Stock performance

18.56 USD (+1.70%)

Close

Last updated: November 19, 2026

1.71B USD

Market cap

Why the stock is moving

As of Nov 19, 2026, GHRS closed up 1.70% at $18.56. No new same-company headline was identified in the current news window.

Company overview

Neuropsychiatric Therapeutics Company

GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders.

GH001

GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals across patients with differing numbers of prior treatment failures.

Delivery and Development Platform

The company is using dedicated inhalation technology and controlled clinical administration to develop short-duration treatments with potentially durable therapeutic effects.

Pivotal Development Path

GH Research is moving GH001 from Phase 2 evidence generation toward pivotal programs in treatment-resistant depression and postpartum depression, with trial designs to be finalized through regulatory interactions.

Future catalysts

  • End-of-Phase 2 FDA meeting for GH001 in treatment-resistant depression in the first quarter of 2027.
  • Initiation of the GH001 pivotal program in treatment-resistant depression shortly after the FDA meeting, subject to final alignment.
  • Initiation of a GH001 pivotal program in postpartum depression in the second half of 2027, subject to regulatory alignment.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of GH Research (GHRS)?

GH Research (GHRS) most recently closed at 18.56 USD, a +1.70% move versus the previous session.

What is the market cap of GH Research (GHRS)?

GH Research currently has a market capitalization of 1.71B USD on BioPharmSignal.

What does GH Research do?

Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders. GH001 GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals across patients...

On which exchange is GHRS stock listed?

GH Research (GHRS) is associated with NASDAQ, Ireland and listed in the U, Biopharma.

What is Neuropsychiatric?

Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders.

Which conditions is GH Research targeting with Neuropsychiatric?

Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders. GH001 GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals across patients...

How does GH Research describe recent progress with Neuropsychiatric?

End-of-Phase 2 FDA meeting for GH001 in treatment-resistant depression in the first quarter of 2027. Initiation of the GH001 pivotal program in treatment-resistant depression shortly after the FDA meeting, subject to final alignment. Initiation of a GH001 pivotal program in postpartum depression in the second half of 2027, subject to regulatory alignment.

What is Therapeutics?

Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders.